Frontiers in Neurology · Oct 31, 2026

Association between Insomnia and Cognitive Impairment in Cerebral Small Vessel Disease: A Systematic Review and Meta-analysis

By Kuihua Wang, Yonghui Liang, Ziyi Gao et al.

Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, and insomnia is increasingly recognized as a modifiable risk factor for cognitive decline. However, the specific quantitative association between insomnia and cognitive impairment in CSVD patients has not been systematically synthesized. Methods: We searched PubMed, EMBASE, Web of Science, and Cochrane Library from inception to April 1, 2026, following PRISMA 2020 guidelines. Observational studies reporting associations between insomnia and cognitive outcomes in neuroimaging-confirmed CSVD patients were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Heterogeneity was quantified by I² statistic. Subgroup analyses, sensitivity analyses, meta-regression, and publication bias assessments were performed. Results: Seventeen studies enrolling 13,157 participants from 11 countries were included. Insomnia was significantly associated with cognitive impairment in CSVD (pooled OR = 2.14, 95% CI: 1.68–2.73, P < 0.001; I² = 58.4%). The association was strongest in white matter hyperintensity (WMH)-predominant CSVD (OR = 2.23, 95% CI: 1.78–2.79) compared to mixed CSVD (OR = 1.93, 95% CI: 1.48–2.52) and lacunar infarct-predominant CSVD (OR = 1.94, 95% CI: 1.49–2.53). Domain-specific analyses revealed the strongest associations for executive function (OR = 2.52) and processing speed (OR = 2.31). Longitudinal studies yielded consistent estimates (OR = 2.08, 95% CI: 1.52–2.84). No significant publication bias was detected (Egger's test P = 0.448). Conclusions: Insomnia is significantly associated with cognitive impairment in patients with cerebral small‑vessel disease (CSVD). Nevertheless, most of the included studies were cross‑sectional, and some samples were recruited from community‑dwelling older adults. These participants met imaging‑based entry criteria for CSVD and comprised both symptomatic and a large number of asymptomatic individuals, leading to substantial heterogeneity in clinical presentations. Accordingly, the observed association cannot be fully attributed to CSVD‑related brain pathology. Residual confounding and reverse causation cannot be ruled out. Our findings support incorporating sleep assessment into clinical workups for CSVD and identify insomnia as a potentially modifiable correlate for cognitive outcomes. Further validation in prospective cohort studies with richer phenotypic data is warranted.

The paperJournal sitePopulations

AgingResearch.News